Don't fool yourself ...The market isn't going to understand the full value of what's going on here - IMO.
They're going to need analysts to explain it to them. Hahaha !
Everything is back on the table - in a big way (it seems).
This is why it's been hard to get information out of these guys.
Lots of science on the go and they can't talk about it until a patent is issued.
As I've been saying - even the commercial study is going to be wrong - the numbers will be too low for the potential of this drug going forward (IMO).
If I am to guess, I'd say we're moving to a (higher purity) Naproxen - only a guess. There are other potential ways but I'd assume they come with greater testing requirements. To be seen.
I think this also puts 352 in question as well - might be able to do double duty if we're lucky. TBD.
Good Luck !